How to Get Retatrutide in South Dakota

What Is Retatrutide and Why Is It Different From Semaglutide or Tirzepatide?

Retatrutide is a once-weekly subcutaneous injection developed by Eli Lilly that simultaneously activates three receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. That triple mechanism separates it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP). The glucagon receptor arm appears to drive additional energy expenditure, which may explain the outsized weight-loss signal seen in early trials.

Phase 2 Trial Results

In the phase 2 trial published in the New England Journal of Medicine (N=338), retatrutide 12 mg produced a mean body weight reduction of 24.2% at 48 weeks versus 2.1% with placebo (Jastreboff et al., NEJM 2023). That figure exceeds the 14.9% mean weight loss seen with semaglutide 2.4 mg at 68 weeks in STEP-1 (N=1,961) and the 20.9% seen with tirzepatide 15 mg at 72 weeks in SURMOUNT-1 (N=2,539) [1].

The trial used a dose-escalation schedule starting at 2 mg weekly and titrating over twelve weeks. Adverse events were predominantly gastrointestinal: nausea occurred in 56% of participants in the 12 mg group versus 25% placebo, consistent with other incretin-based therapies [1].

Where Phase 3 Stands

Phase 3 trials (TRIUMPH program) are ongoing as of mid-2025. No FDA approval for retatrutide exists yet. That regulatory gap is what creates the compounding pharmacy pathway described later in this article.

Is Retatrutide Legal to Prescribe in South Dakota?

Yes. South Dakota law permits licensed physicians, nurse practitioners, and physician assistants to prescribe compounded medications for individual patients when a valid patient-prescriber relationship exists. Telehealth prescribing is also legal in South Dakota under S.D. Codified Laws § 36-4-41, meaning an out-of-state telehealth provider holding a South Dakota license or a compact license may write a prescription for a South Dakota resident.

Federal Compounding Law

Under the federal Drug Quality and Security Act, a 503A compounding pharmacy may prepare a drug for an identified individual patient based on a valid prescription. Retatrutide is not on the FDA's list of drugs that may not be compounded. A compounding pharmacy must use pharmaceutical-grade active pharmaceutical ingredient (API) and operate under state board of pharmacy oversight.

The FDA has issued guidance indicating that compounded versions of GLP-1 receptor agonists occupy a complex legal space, particularly when a branded drug is available commercially. Because no branded retatrutide product is currently on the market, that specific restriction does not yet apply. Prescribers and pharmacies should monitor FDA guidance as phase 3 data emerge (FDA compounding guidance).

State Board of Pharmacy Position

South Dakota's Board of Pharmacy licenses 503A compounding pharmacies operating within state lines and recognizes out-of-state pharmacies licensed in their home state that register with South Dakota. Patients should confirm that any online pharmacy shipping retatrutide to a South Dakota address holds valid registration in both its home state and South Dakota.

How to Get a Retatrutide Prescription in South Dakota: Step by Step

Getting started takes roughly five steps. Short timelines below reflect typical telehealth workflows.

Step 1: Order Baseline Labs (Days 1 to 3)

A prescriber will require recent laboratory results before writing a retatrutide prescription. Standard pre-treatment labs include:

• Comprehensive metabolic panel (CMP)
• Hemoglobin A1c
• Fasting lipid panel
• Thyroid-stimulating hormone (TSH)
• Complete blood count (CBC)
• Fasting insulin and glucose (optional but informative)

Results from within the past ninety days are generally acceptable. South Dakota residents can order these through Sanford Health, Avera, or any regional lab. Telehealth platforms such as HealthRX can also send standing lab orders to a Quest or LabCorp location in Sioux Falls, Rapid City, Aberdeen, or Watertown.

Step 2: Schedule a Telehealth Consultation (Days 3 to 5)

A board-certified prescriber reviews your labs, medical history, current medications, and weight history during a video or asynchronous consultation. Expect questions about prior GLP-1 use, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (both are contraindications), pancreatitis, and current diabetes medications.

The consultation typically lasts twenty to forty minutes for a synchronous visit or is completed within forty-eight hours for asynchronous review.

Step 3: Prescription Sent to a Licensed 503A Pharmacy (Days 5 to 7)

Once approved, the prescriber transmits the prescription electronically to a partner 503A compounding pharmacy. The pharmacy prepares retatrutide using pharmaceutical-grade API, typically suspended in bacteriostatic water, and dispenses it in multi-dose vials or pre-filled syringes.

South Dakota allows mail-order delivery of compounded injectables when the pharmacy holds valid state registration. Shipping from most partner pharmacies to South Dakota addresses takes two to five business days with temperature-controlled packaging.

Step 4: Injection Training and Monitoring Setup (Day 7 Onward)

Self-injection training is available via telehealth video. Retatrutide is injected subcutaneously into the abdomen, thigh, or upper arm once weekly, rotating sites. The prescriber establishes a titration schedule aligned with the phase 2 protocol: typically 2 mg weekly for four weeks, then 4 mg weekly, escalating by 2 mg every four weeks to a target of 8 mg or 12 mg based on tolerability.

Step 5: Monthly Check-Ins and Lab Monitoring

Follow-up visits occur monthly for the first three months, then quarterly. Repeat HbA1c and metabolic panel at three months. Weight, blood pressure, and heart rate are tracked at each visit. Patients using insulin or sulfonylureas concurrently require closer glucose monitoring given the additive hypoglycemic risk.

Who Can Prescribe Retatrutide in South Dakota?

Three provider types hold prescriptive authority in South Dakota for Schedule and non-Schedule prescription medications, including compounded injectables.

Medical Doctors (MD) and Doctors of Osteopathy (DO)

MDs and DOs practicing in South Dakota or holding a compact license through the Interstate Medical Licensure Compact may prescribe retatrutide. Obesity medicine specialists and endocrinologists are most familiar with incretin-based therapy titration, but any licensed physician may prescribe after conducting a proper evaluation.

Nurse Practitioners (APRN)

South Dakota grants full practice authority to APRNs under S.D. Codified Laws § 36-9A. An NP may independently prescribe controlled and non-controlled medications without physician oversight. Telehealth NPs licensed in South Dakota routinely prescribe compounded GLP-1 agents.

Physician Assistants (PA)

PAs in South Dakota prescribe under a collaborative agreement with a supervising physician. That agreement must cover the drug class being prescribed. Most telehealth platforms that use PA providers ensure the collaborative agreement explicitly includes compounded peptides and GLP-1 analogs.

Dosing Protocol for Retatrutide

The phase 2 trial used a structured escalation schedule. No FDA-approved label exists yet, so prescribers base dosing on published trial data (Jastreboff et al., NEJM 2023) and clinical judgment.

| Week | Dose (mg, subcutaneous weekly) | |------|-------------------------------| | 1 to 4 | 2 mg | | 5 to 8 | 4 mg | | 9 to 12 | 6 mg | | 13 to 16 | 8 mg | | 17 to 20 | 10 mg | | 21+ | 12 mg (if tolerated) |

Patients who experience persistent nausea, vomiting, or more than a 20% heart rate increase should hold the dose escalation for an additional four weeks at the current dose before attempting to advance. The phase 2 trial recorded a mean heart rate increase of 5.8 beats per minute at the 12 mg dose, a finding consistent with glucagon receptor activation [1].

Cost and Insurance Coverage in South Dakota

Retatrutide has no FDA-approved commercial form yet, so no insurance formulary covers it. South Dakota Medicaid explicitly excludes investigational compounds from coverage.

Out-of-pocket costs at licensed 503A compounding pharmacies typically break down as follows:

• Initial telehealth consultation: $75 to $199
• Monthly supply (4 doses, 8 mg each): $250 to $450
• Monthly supply (4 doses, 12 mg each): $350 to $600
• Follow-up telehealth visits: $49 to $99 per visit
• Quarterly labs: $80 to $150 depending on the panel

Prices vary by pharmacy and do not include shipping, which runs $15 to $30 for cold-chain delivery. Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) may cover compounded prescription medications when prescribed for a diagnosed condition such as obesity (ICD-10 E66.01) or type 2 diabetes (ICD-10 E11.9). Confirm eligibility with your HSA administrator before assuming reimbursement.

Comparing Retatrutide to Other GLP-1 Options Available in South Dakota

South Dakota residents have access to several FDA-approved GLP-1 and dual-agonist medications through standard pharmacy channels. The table below places retatrutide in clinical context.

| Drug | Mechanism | Peak Weight Loss (Trial) | FDA Approval | SD Medicaid | |------|-----------|------------------------|-------------|-------------| | Semaglutide 2.4 mg (Wegovy) | GLP-1 | 14.9% at 68 weeks (STEP-1) | Yes (2021) | Limited | | Tirzepatide 15 mg (Zepbound) | GLP-1 + GIP | 20.9% at 72 weeks (SURMOUNT-1) | Yes (2023) | Not covered | | Retatrutide 12 mg | GLP-1 + GIP + glucagon | 24.2% at 48 weeks (phase 2) | No | Not covered |

For patients who have already tried semaglutide or tirzepatide and achieved inadequate weight loss (defined as <5% body weight reduction at twelve weeks on a maintenance dose), retatrutide may offer additional benefit through its distinct glucagon receptor pathway. That clinical threshold aligns with the American Association of Clinical Endocrinology 2023 obesity guideline recommendation to reassess therapy when initial response is insufficient (AACE 2023 Obesity Guidelines).

Contraindications and Safety Considerations

Retatrutide shares class-level contraindications with other incretin therapies. A prescriber must rule out the following before initiating therapy:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia type 2 (MEN2)
• Active or recent pancreatitis
• Pregnancy or active breastfeeding
• Severe gastroparesis

The FDA's prescribing information for semaglutide (Ozempic) includes a boxed warning for thyroid C-cell tumors based on rodent studies. The same mechanistic concern applies to other GLP-1 receptor agonists, including retatrutide, even though no human cases of medullary thyroid carcinoma have been causally attributed to GLP-1 therapy in clinical trials (FDA Ozempic label).

Drug Interactions

Retatrutide slows gastric emptying, which may reduce peak plasma concentrations of orally administered drugs that depend on rapid absorption. Oral contraceptives, thyroid replacement, and immunosuppressants should be taken at a consistent time relative to meals. Consult a pharmacist about any time-sensitive oral medications.

Monitoring Parameters

The American Diabetes Association Standards of Care recommend that patients starting any GLP-1 based therapy receive baseline and follow-up renal function testing, as acute kidney injury has been reported secondary to dehydration from GI side effects (ADA Standards of Care 2024). Creatinine and eGFR should be checked at the three-month visit.

Telehealth Platforms Serving South Dakota for Retatrutide

South Dakota's low population density (11.3 people per square mile per the 2020 census) means most residents live more than thirty miles from an obesity medicine specialist. Telehealth removes that barrier entirely. The following characteristics distinguish a high-quality telehealth platform for retatrutide access:

• Prescribers licensed in South Dakota or holding an active compact license
• In-house or partner 503A compounding pharmacy registered in South Dakota
• Asynchronous lab review to reduce wait times
• Structured titration protocols based on published phase 2 data
• Monthly check-ins with objective weight and metabolic tracking

HealthRX operates across South Dakota and connects patients to board-certified prescribers who review labs within forty-eight hours. The platform ships compounded retatrutide from a registered 503A pharmacy to all South Dakota ZIP codes, including rural addresses in the western Black Hills region.

Transferring a Retatrutide Prescription to South Dakota

Patients who initiated retatrutide in another state and have relocated to South Dakota may transfer their prescription. The steps are straightforward:

1. Contact the original prescribing platform and request a prescription transfer or a new prescription to a South Dakota-registered pharmacy.
2. Confirm the receiving pharmacy holds valid South Dakota registration.
3. Share recent lab results (within ninety days) and the current dose with the new prescriber for continuity.
4. A South Dakota-licensed prescriber must co-sign or issue a new prescription if the original prescriber is not licensed in South Dakota.

Prescription transfers for controlled substances have separate requirements under DEA rules, but retatrutide is not a scheduled substance, so standard prescription transfer rules apply.

Frequently Asked Questions